Kindred Biosciences (KIN) Given a $11.00 Price Target at B. Riley
Kindred Biosciences (NASDAQ:KIN) has been assigned a $11.00 price objective by B. Riley in a note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s price target points to a potential upside of 46.67% from the company’s current price.
Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research note on Wednesday, September 6th. HC Wainwright initiated coverage on shares of Kindred Biosciences in a research note on Friday, November 17th. They issued a “buy” rating and a $9.50 target price on the stock. Finally, ValuEngine raised shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Friday. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Kindred Biosciences presently has a consensus rating of “Buy” and a consensus price target of $9.63.
Shares of Kindred Biosciences (KIN) traded down $0.10 on Tuesday, reaching $7.50. The company’s stock had a trading volume of 85,800 shares, compared to its average volume of 144,079. Kindred Biosciences has a 12 month low of $3.90 and a 12 month high of $9.65.
A number of institutional investors have recently bought and sold shares of the stock. Virtu KCG Holdings LLC increased its holdings in Kindred Biosciences by 41.7% in the 2nd quarter. Virtu KCG Holdings LLC now owns 15,285 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 4,495 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Kindred Biosciences by 28.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 4,954 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Kindred Biosciences by 2.2% in the third quarter. Wells Fargo & Company MN now owns 337,608 shares of the biopharmaceutical company’s stock worth $2,650,000 after acquiring an additional 7,206 shares in the last quarter. Prudential Financial Inc. grew its stake in shares of Kindred Biosciences by 18.9% in the third quarter. Prudential Financial Inc. now owns 52,920 shares of the biopharmaceutical company’s stock worth $415,000 after acquiring an additional 8,410 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Kindred Biosciences by 17.5% in the third quarter. Bank of New York Mellon Corp now owns 74,548 shares of the biopharmaceutical company’s stock worth $586,000 after acquiring an additional 11,081 shares in the last quarter. Hedge funds and other institutional investors own 66.85% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/05/kindred-biosciences-kin-given-a-11-00-price-target-at-b-riley.html.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.